Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.7% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a pharmaceutical company with a focus on developing treatments for neurodegenerative diseases. The stock saw a notable downward trend in the market today.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.7% on May 7, 2025 14:10

• A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
• The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
• The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
• Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Amylyx Pharmaceuticals ( NASDAQ:AMLX ) , Bank First ( NASDAQ:BFC )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Leerink Partners analyst Marc Goodman upgraded the rating for Amylyx Pharmaceuticals, Inc.

https://www.benzinga.com/25/05/45249685/this-logitech-international-analyst-turns-bullish-here-are-top-4-upgrades-for-wednesday

Trending Today

Ondo ($ONDO) Crypto Forecast: Up 5.4% Today

Visa Inc. ($V) Stock Forecast: Down 5.1% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 5.2% Today

Mastercard Incorporated ($MA) Stock Forecast: Down 5.1% Today

Applovin Corporation ($APP) Stock Forecast: Down 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 18.4% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Carvana Co ($CVNA) Stock Forecast: Up 5.2% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 5.3% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 6.6% Today

Amylyx Pharmaceuticals Price History

17.08.2024 - AMLX Stock was up 10.3%

• Recent executive purchases of shares in Reneo Pharmaceuticals and other stocks priced below $5 could signal optimism towards the pharmaceutical sector, potentially benefiting similar companies like AMLX.
• The market's bullish trend, reflected in the Dow Jones index, likely created a favorable atmosphere for small-cap stocks such as AMLX to perform well.
• The insider buying activity may have been viewed by investors and traders as a show of support for the industry, leading to increased interest in AMLX and driving its positive movement.

18.10.2024 - AMLX Stock was up 7.1%

• The bullish movement in AMLX could be attributed to positive analyst sentiment and upgrades in the online trading sector, similar to recent developments with other companies in the industry.
• This change in outlook by analysts may have instilled confidence in investors, leading to increased buying activity and driving the stock price higher.
• The overall optimism in the online trading industry, as indicated by the analyst upgrades, likely contributed to the positive momentum seen in AMLX today.

07.04.2025 - AMLX Stock was down 5.7%

• A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
• The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
• The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
• Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

09.04.2024 - AMLX Stock was down 7.8%

• AMLX experienced a notable financial setback in Q1, falling considerably short of revenue forecasts.
• This disappointing financial performance likely heightened investor anxieties and triggered a downward trend in the stock price.
• AMLX's upcoming participation in the Bank of America Health Care Conference presents an opportunity for the company to address issues, unveil future strategies, and potentially impact stock performance.

10.04.2024 - AMLX Stock was up 8.3%

• Despite missing both EPS and revenue estimates for Q1 2024, Amylyx Pharma's stock displayed strong bullish movement.
• Market sentiment seems to be influenced by the company's upcoming participation in the 2024 Bank of America Health Care Conference, suggesting anticipated positive developments.
• Investors may hold optimistic views regarding Amylyx Pharmaceuticals' future outlook, showing interest in potential updates from the conference despite the Q1 results.
• The bullish trend could be linked to investors acknowledging the long-term value of the company's efforts in addressing neurodegenerative diseases, despite the Q1 2024 financial performance shortfall.

11.06.2024 - AMLX Stock was up 12.6%

• The purchase of avexitide from Eiger BioPharmaceuticals for $35.1 million elevated investor confidence in Amylyx Pharmaceuticals, resulting in a notable increase in the stock price.
• FDA's Breakthrough Therapy Designation for avexitide in addressing post-bariatric hypoglycemia and congenital hyperinsulinism underscored the drug's potential, drawing heightened interest from investors.
• Anticipation for the Phase 3 trials scheduled in 2025 and positive outcomes from Phase 2 trials further bolstered optimism surrounding Amylyx Pharmaceuticals, driving up the stock price.
• The announcement of an upcoming conference call to discuss the acquisition stoked speculation and market interest in the company, contributing to the positive market movement.

10.06.2024 - AMLX Stock was up 7.0%

• Amylyx Pharmaceuticals saw a strong bullish movement today.
• The recent acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation has had a positive impact on the stock.
• The market is responding positively to the potential future promise highlighted by the acquisition and the successful Phase 2 trials.
• An upcoming conference call to discuss the acquisition could offer additional insights and momentum for AMLX stock.

10.06.2024 - AMLX Stock was up 24.6%

• AMLX stock rose notably after the company announced its acquisition of the Phase 3-ready GLP-1 receptor antagonist, Avexitide, which has received FDA Breakthrough Therapy Designation, indicating a promising outlook for the company.
• The favorable results from Phase 2 trials and the FDA Breakthrough designation fueled investor confidence, leading to a surge in the stock price.
• Investors reacted positively to Amylyx Pharmaceuticals' expansion of its endocrine portfolio through the $35.1M acquisition, paving the way for Phase 3 trials scheduled in 2025.
• The anticipation surrounding an upcoming conference call to discuss the acquisition further strengthened investor belief in the company's growth strategy, contributing to the bullish trend in AMLX stock.

12.02.2025 - AMLX Stock was up 12.4%

• Amylyx Pharmaceuticals (AMLYX) experienced a strong bullish movement.
• The positive market sentiment and the overall bullish trend in the market could have contributed to the surge in AMLYX stock.
• There were no specific negative news related to AMLYX mentioned, indicating that the bullish movement might be more driven by market factors rather than company-specific news.
• Investors might be optimistic about the future prospects of Amylyx Pharmaceuticals, leading to increased buying interest and pushing the stock price higher.

13.07.2024 - AMLX Stock was up 5.0%

• AMLX stock experienced a strong bullish movement today.
• The bullish trend can be attributed to the encouraging data revealed on the effects of AMX0035 on cerebrospinal fluid biomarkers related to Alzheimer's disease pathology and neurodegeneration.
• The positive results from the Phase 2 trial, showing reduced tau levels and engagement of multiple pathological pathways, have likely boosted investor confidence in the potential of AMX0035 as a treatment for neurodegenerative diseases.
• The company's recent financial report for Q2 2024 may have also contributed to the positive sentiment surrounding AMLX stock, indicating a strong pipeline with assets targeting orphan indications and FDA Breakthrough Therapy Designation for one of their drugs.

09.07.2024 - AMLX Stock was up 5.1%

• The recent expansion of its late-stage pipeline with the acquisition of avexitide, a Phase 3-ready asset with FDA Breakthrough Therapy Designation, may have driven the bullish movement in AMLX stock.
• Despite a decline in revenue and net loss in the second quarter, investors appear optimistic about the company's pipeline expansion and progress in trials for avexitide and other assets.
• The market's positivity towards Amylyx Pharmaceuticals' new assets targeting orphan indications likely influenced the bullish movement in AMLX stock today.

08.07.2024 - AMLX Stock was down 5.2%

• Amylyx Pharmaceuticals (AMLYX) experienced a significant decline in revenue and a net loss in their Q2 2024 financial results.
• Despite obtaining Orphan Drug Designation for AMX0035 in Wolfram Syndrome from both the FDA and the European Commission, the market's reaction to the company's overall financial performance was negative.
• The acquisition of avexitide and the drug's Phase 3 readiness with FDA Breakthrough Therapy Designation could not counteract the bearish sentiment influenced by the financial results.
• Investors appear to have concerns about Amylyx Pharmaceuticals' capacity to convert its promising pipeline into sustainable revenue growth, which has contributed to the downward movement in AMLYX stock.